

Corporate Overview

May 20, 2021

Marcel R. Gamma
President & CEO

Market Data

Symbol:	OTC - CBDD
Fiscal Year:	December
Industry:	Technology

Legal Disclaimer

This presentation contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of CBD of Denver Inc. (the "Company") with members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


The presentation is intended to be used and must be used for informational purposes only. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find in this presentation or on our website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy of such third-party information. We did not make an independent investigation or inquiry as to the accuracy of any information provided by third party sources. All information regarding the Company itself is contained in other publicly available press releases or filings made by the Company including reports posted on OTCMarkets.com.

Independent accountants have neither audited, reviewed, examined nor compiled any of the historical, pro forma, budgeted or prospective financial information presented herein or expressed any opinion or conclusion thereon or any other form of assurance with respect thereof.

The presentation does not take into account the investment objectives, financial situation, or particular needs of any particular person. The presentation does not provide all information material to an investor's decision about whether or not to make any investment. Companies that typically trade on the OTC market, such as the Company, are at an early stage in their evolution, tend to trade with big price swings and typically carry above-average risk profiles. Any discussion of risks is not a disclosure of all risks or a complete discussion of the risks mentioned.

Intro




- ✿ OTC-listed US Company «CBDD»
- ✿ Headquarter in Denver, Colorado
- ✿ Two subsidiaries in Switzerland
- ✿ Building Group of Companies in the area of CBD and Cannabis
- ✿ Focusing on Swiss and European Market

Achievements

- ✓ 3 Acquisitions successfully closed
- ✓ USD 16.5 Mio Revenue for 2020 achieved and profitable
- ✓ USD 7.5 Mio Revenue for Q1/2021 achieved and profitable
- ✓ Guidance for 2021 at USD 22 Mio and with trailing revenue over past 12 months already at USD 24.4 Mio
- ✓ Solid Client-Base established in Switzerland and the entire European Market and continuously increasing
- ✓ Further expanding in new high-margin business (Online Retail / B2B)
- ✓ Strong online presence (Internet, Social Media, Webshop, etc.)



Swiss & European CBD Market



- ✦ Switzerland in the «heart» of the European Market
- ✦ European Market with a population of **746.4 million** (double size US Market) ¹⁾
- ✦ Cannabis Industry is still in its infancy stages in Switzerland and Europe
- ✦ Exponential **Market Growth of 400%** over the next 4 years ¹⁾
- ✦ CBD market projected to be worth at least **€13.6 billion by 2025** ²⁾

1) Source: Brightfield Group Report

2) Source: New Frontier Data

Growth Strategy – Acquisition

- ✓ Expanding through **Buying Swiss Competitors**
 - 8-10 potential targets identified and approached
 - 2-4 potential targets under review
 - 3 potential targets already in negotiation phase

- ✓ **European Distribution Center** in Austria

- ✓ Extremely **attractive multiples** compared to US and Canadian Market

- ✓ Cash Flow **positiv and accretive**

Growth Strategy – Wholesale

Increasing Volume of **Flower-Imports & Sales**

- ✦ Develop Import from other countries global
- ✦ Acquire new Suppliers in EU / US / Canada / South Americas
- ✦ Expand Client & Partners Network

Expanding **Portfolio & New Markets**

- ✦ Add new Products to Portfolio
- ✦ Build up Distribution Network in EU



Growth Strategy – Retail & B2B

Build up new **Call Center**


- ✦ Direct Acquisition of new Clients throughout all Europe
- ✦ Strengthen Sales Support for our Account Teams

Development of **Rockflowr Brand**

- ✦ Continuously expand Product Portfolio for Retail & B2B
- ✦ Strengthen Market Presence through focused Marketing and Social Media activities
- ✦ Development of new Webshop and Product Landing Pages



Investment – Why invest?



- ✦ Ability to buy CBD companies through our network at very attractive prices
- ✦ Swiss & European Cannabis Industry is in its Infancy Stage and about 10-15 year behind US and CDN
- ✦ 3 additional acquisitions under negotiation
- ✦ USD 16.5 Mio Revenue in 2020 and USD 7.5 Mio Revenue for Q1/2021 profitable
- ✦ Trailing Revenue of USD 24.4 Mio over past 12 months ending April 2021
- ✦ The average multiple of 12.4 times enterprise value as per Haywood Capital Markets


Investment – Valuation at Revenue Generating Stage

Company	Last Deal Date	Revenue \$ million	Valuation / Revenue	Implied Valuation	EBITDA Margin	Total Production
Pedianos (GER)	17-May	3.8	5.5X	20.9	N/A	N/A
Future Harvest Dev (CAN)	15-May	5	11.2X	55.6	N/A	N/A
Tahoe Hydro (USA)	18-Aug	6.2	6.5X	40.2	32.30%	1,1K - 2.2K KG
Emblem (CAN)	18-Dec	7.4	18.1X	68.1	N/A	1,6K KG
CBD of Denver (USA)	Projection	24.4	10.0X	244	N/A	N/A
Canna Farm (CAN)	18-Aug	9.4	14.15X	133	45.70%	2,5K – 3,5K KG
Other: Indiva (CAN)	N/A	14	6.14X	86	N/A	N/A
Source: Pitchbook		Average	10.26			

- Over past **12 months** (May 2020 to April 2021) **trailing revenue of USD 24.4 Million**
- Due to the regulatory environment in Switzerland, **Swiss companies are valued much higher EV/R multiple** than similar companies in other countries. However, we used a **very conservative EV/R multiple** to determine our potential valuation.
- This valuation does not take into consideration any future expansion and revenue growth generated from high-margin growth channels.
- Based on Haywood Capital Market the average multiple for Cannabis Industry is 12.4 times enterprise value.

Contact

CBD



of Denver, Inc.

CBD of Denver, Inc.

Marcel R. Gamma – President & CEO

M.A. Economics & Finance (lic. oec. HSG) / MBA

marcel@cbdofdenver.com